<SUBMISSION>
<ACCESSION-NUMBER>0001193125-09-177955
<TYPE>8-K
<PUBLIC-DOCUMENT-COUNT>3
<PERIOD>20090819
<ITEMS>8.01
<ITEMS>9.01
<FILING-DATE>20090819
<DATE-OF-FILING-DATE-CHANGE>20090819
<FILER>
<COMPANY-DATA>
<CONFORMED-NAME>CERUS CORP
<CIK>0001020214
<ASSIGNED-SIC>3841
<IRS-NUMBER>680262011
<STATE-OF-INCORPORATION>DE
<FISCAL-YEAR-END>1231
</COMPANY-DATA>
<FILING-VALUES>
<FORM-TYPE>8-K
<ACT>34
<FILE-NUMBER>000-21937
<FILM-NUMBER>091023020
</FILING-VALUES>
<BUSINESS-ADDRESS>
<STREET1>2411 STANWELL DR
<CITY>CONCORD
<STATE>CA
<ZIP>94520
<PHONE>9252886000
</BUSINESS-ADDRESS>
<MAIL-ADDRESS>
<STREET1>2525 STANWELL DRIVE
<STREET2>STE 300
<CITY>CONCORD
<STATE>CA
<ZIP>94520
</MAIL-ADDRESS>
<FORMER-COMPANY>
<FORMER-CONFORMED-NAME>CERUS TECHNOLOGIES INC
<DATE-CHANGED>19960731
</FORMER-COMPANY>
</FILER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML><HEAD>
<TITLE>Form 8-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">
 <P STYLE="line-height:0px;margin-top:0px;margin-bottom:0px;border-bottom:0.5pt solid #000000">&nbsp;</P> <P
STYLE="line-height:3px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000">&nbsp;</P> <P STYLE="margin-top:3px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="5"><B>UNITED STATES </B></FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="5"><B>SECURITIES AND EXCHANGE COMMISSION </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman"
SIZE="3"><B>Washington, D.C. 20549 </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P
STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="5"><B>FORM 8-K </B></FONT></P> <P
STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12px;margin-bottom:0px"
ALIGN="center"><FONT FACE="Times New Roman" SIZE="3"><B>CURRENT REPORT </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="3"><B>Pursuant to Section&nbsp;13 or 15(d) of the </B></FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="3"><B>Securities Exchange Act of 1934 </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman"
SIZE="2"><B>Date of Report (Date of earliest event reported): August&nbsp;19, 2009 </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P
STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="6"><B>CERUS CORPORATION
</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>(Exact name of registrant as specified in its charter) </B></FONT></P> <P
STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P
STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>Delaware</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>0-21937</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>68-0262011</B></FONT></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>(State or other jurisdiction</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT
FACE="Times New Roman" SIZE="1"><B>of incorporation)</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>(Commission File No.)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>(IRS Employer</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT FACE="Times New Roman"
SIZE="1"><B>Identification No.)</B></FONT></P></TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>2411 Stanwell Drive </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"
ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>Concord, California 94520 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>(Address of principal executive offices and zip
code) </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>Registrant&#146;s telephone number, including area code: (925)&nbsp;288-6000 </B></FONT></P> <P
STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
FACE="Times New Roman" SIZE="2">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions. </FONT></P> <P
STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2"><FONT FACE="WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) </FONT></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2"><FONT FACE="WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) </FONT></TD></TR></TABLE> <P
STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2"><FONT FACE="WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) </FONT></TD></TR></TABLE> <P
STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2"><FONT FACE="WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) </FONT></TD></TR></TABLE> <P
STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="line-height:3px;margin-top:0px;margin-bottom:0px;border-bottom:0.5pt solid #000000">&nbsp;</P> <P
STYLE="line-height:3px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><B>Item&nbsp;8.01. Other Events. </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
FACE="Times New Roman" SIZE="2">On August&nbsp;19, 2009, Cerus Corporation (the &#147;Company&#148;) announced that the Swiss regulatory body, Swissmedic, has approved the use of platelet components treated with the Company&#146;s INTERCEPT Blood
System. A copy of the Company&#146;s press release, entitled &#147;Cerus&#146; INTERCEPT Blood System for Platelets Receives Swiss Approval,&#148; is filed as Exhibit 99.1 hereto and is incorporated herein by reference. </FONT></P> <P
STYLE="margin-top:18px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><B>Item&nbsp;9.01. Financial Statements and Exhibits. </B></FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2"><B>(d)</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><B>Exhibits</B> </FONT></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="1"><B>Exhibit</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000;width:28pt"><FONT
FACE="Times New Roman" SIZE="1"><B>Number</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="border-bottom:1px solid #000000;width:39pt"><FONT FACE="Times New Roman" SIZE="1"><B>Description</B></FONT></P></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">99.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">Press Release, dated August&nbsp;19, 2009, entitled &#147;Cerus&#146; INTERCEPT Blood System for Platelets Receives Swiss Approval.&#148;</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">1. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>SIGNATURE </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
FACE="Times New Roman" SIZE="2">Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. </FONT></P> <P
STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0">

<TR>
<TD WIDTH="43%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="9%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="2%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="43%"></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="3"><FONT FACE="Times New Roman" SIZE="2"><B>CERUS CORPORATION</B></FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Dated: August&nbsp;19, 2009</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">By:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT FACE="Times New Roman" SIZE="2">/s/&nbsp;&nbsp;&nbsp;&nbsp;Kevin D. Green</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">Kevin D. Green</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">Vice President, Finance and Chief</FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT FACE="Times New Roman" SIZE="2">Accounting Officer
</FONT></P></TD></TR>
</TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">2. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>EXHIBIT INDEX </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="5%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="1"><B>Exhibit</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000;width:28pt"><FONT
FACE="Times New Roman" SIZE="1"><B>Number</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="border-bottom:1px solid #000000;width:39pt"><FONT FACE="Times New Roman" SIZE="1"><B>Description</B></FONT></P></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-left:1.00em; text-indent:-1.00em" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">99.1</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">Press Release, dated August&nbsp;19, 2009, entitled &#147;Cerus&#146; INTERCEPT Blood System for Platelets Receives Swiss Approval.&#148;</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">3. </FONT></P>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>dex991.htm
<DESCRIPTION>PRESS RELEASE
<TEXT>
<HTML><HEAD>
<TITLE>Press Release</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2"><B>Exhibit 99.1 </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px">

<IMG SRC="g58151g16u02.jpg" ALT="LOGO"> </P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><B>Cerus&#146; INTERCEPT Blood System for Platelets Receives Swiss Approval </B></FONT></P> <P
STYLE="margin-top:6px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">CONCORD, Calif.&#151;(BUSINESS WIRE)&#151;Aug 19, 2009&#151; Cerus Corporation (NASDAQ:CERS) announced today that the Swiss regulatory body, Swissmedic, has approved the
use of platelet components treated with Cerus&#146; INTERCEPT Blood System. The approval extends permitted storage time for platelets to seven days with INTERCEPT treatment, compared to five days without treatment. </FONT></P> <P
STYLE="margin-top:12px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">The regulatory review process by Swissmedic is similar to the regulatory processes in France (Afssaps) and Germany (Paul Ehrlich Institute), in which INTERCEPT-treated
blood components have been approved as a biologic for patient use. Cerus has previously received CE mark approval for its INTERCEPT platelet and plasma systems, which allows Cerus to sell the systems in the European Union. </FONT></P> <P
STYLE="margin-top:12px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">The INTERCEPT platelet system has been piloted in Basel over the past three years and also has been used in clinical studies elsewhere in Switzerland. It is estimated
that Switzerland produces approximately 20,000 platelet doses and 75,000 plasma units for transfusion annually. The INTERCEPT plasma system is under review by Swissmedic. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT
FACE="Times New Roman" SIZE="2"><B>ABOUT CERUS </B> </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">Cerus Corporation is a biomedical products company focused on commercializing the INTERCEPT Blood
System to enhance blood safety. The INTERCEPT Blood System is designed to inactivate blood-borne pathogens in donated blood components intended for transfusion. Cerus currently markets the INTERCEPT Blood System for both platelets and plasma in
Europe, Russia, the Middle East and selected countries in other regions around the world. The INTERCEPT red blood cell system is currently in clinical development. See http://www.cerus.com for more information. </FONT></P> <P
STYLE="margin-top:12px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">INTERCEPT and the INTERCEPT Blood System are trademarks of Cerus Corporation. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT FACE="Times New Roman"
SIZE="2">Contact: </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">Lainie Corten </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">Director, Global
Communications&nbsp;&amp; Marketing </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">Cerus Corporation </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">(925)
288-6319 </FONT></P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g58151g16u02.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g58151g16u02.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D
M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"
M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#_\``$0@`*@"D`P$1``(1`0,1`?_$`-4```$#!0$!````````
M``````H`"`D#!`8'"P(%`0`"`P`#`0$``````````````0(#!`8'"0@%$```
M!0(#!`,)"0@,#P`````!`@,$!08'`!$((1(3"3$4%B(T%34V%S<X"D$R4F)3
M8Q@9.6'1(S,D95:7451DE-1&9E=W>+@Z<9'A0L+20Y,EM99'9[<:$0`!`P$$
M!08)"`@'```````!``(#$2$$!0<Q01(R!E%A<1,T")'1(D)2594V&('!8I(S
M0U07H=)38],4-9:"PB,D1)0W_]H`#`,!``(1`Q$`/P`R/7GKVL'R[K$S%]K]
MS;AO&(JC%TE2,,1NYJVOZH42,JUIJEV#A=LBN\4(45%555$V[9`IE%3E(41P
M*36EYH%"/9Z)YS_-HB8V\]37P+RQ=*%5D/)6\HNV42,YJ!JZE7OX1C(5`XFD
MDF3:+F(\X`(.3,7*8FS(B<O="*P[$=E*N6[%_9W;4SC-P[K;6MK3JNLW#44#
M56:Y+:*3%0B9B-53P;5FJV.1L(Y[G%#>#8(ATX$NM(T`)F^HWE`\UK292$U<
M7EU<R>]5P4Z>8J2K^R=P'49#S,Q&Q*)CIQ--2@MI:,J)]U=/8D]6CQ/END,8
MXE`12#V.WQ:GN\I;5;JRU+\I^M;[7TJB6EKV-:IO)3<3/-(M*.FT#414#R#;
MMRQB(.#D?QSEJ9,=Y/,YBB(!ECK'.;$<;PG*S',2X<DFBQR'#I70/B%9&R!O
MDE@H:NKHL*Y[E=<,'Q',?!\/QR.*3!Y;[&V5LII&YA-H>:BSEM"OH74+KM4:
M%!@SN1,I9$-UH]OIJ0.(&+F416;QX$W3AM#9MQY@X7G1WN'W>ESBQR]1V>6<
M.GD.BSRFQTM7H3B.5'=D;/\`[J3"+N^WR1?H8QIY'/K8OK_2`U^?HY<;]5]0
M_P``Q^E^<G?$_`XW[*O/\-8/RK[K?XO"/:,'ZZ7T@-?GZ.7&_5?4/\`P?G)W
MQ/P.-^RKS_#1^5?=;_%X1[1@_76XM*-X-3E8ZB*9@[J/ZX;TRYAJM<NXF6@'
M<-$JN&T0L=F94KIBD("W=%#AAOAD<,MN.R^[QF7GUQ-G5<,*S!FQ9F`R76^.
M?#-=WP0ES826$[;!NOW?*TV6KK_/'@#)G`,IKYB7!$6&OQEEXNK62Q3MEE#7
M2@/ILO.\W>LT*KJ`T.<P:\.H&N*[MUS.ZZTYV8F2Q84C;&B;:P%6N:?,SBT&
M[XRKB>=Q:)O"$B4ZILE3[I1V;=F/2]?`@<P"T5*C$UMTGSUN6]0$WJ-LWK)A
MM;5IJ$0-.W%IBZ=L6#"N(>`;D(20E&M.PL@1@_A&2&:BPMGRCQ,0$Y4A`,"F
MWJW6$4*D9Y-W.`H3FFVLJ+KU.M;<:@;8=6)<RW39\:1C5HMZ<$8JM*6>K$1=
M+P,HK^"4(LFFHV=E.EW92E4,*,C-@\RQKG04_J1LSI=U`:Q=.^KV\EIJGM?2
MK&K"VY:+PTG;9Y'P2#%A(,&$4XC>NQCR5(0RZBW&4`S@YAR*`[!$="X-(TJ-
M#V?2_&MOF2DNU>O49K*NRI3EH*YIBF(BVM&DA:?AI]T2'8SCUQ43HS!XX<QS
M]N\(BH@3<$Q@,;>#/+""G(&ML`1>V&J%K"[]NI&Z=$O:1B;D5_:E^Y=-':%9
M6UE&D34[([0YC@W3<OF,@W.Q=";)9,4\U"AEO!TX$!!TT_>/F2/^=O4O*Q>\
MP6Z*EK:;<]LEK@(PT$A73JC7ENZ:N`UIY-P#51JE)H-*C2;&6$NX*J9U,^Z`
M,&M7T;L;=+5.WS..930_**TM4C(SJ]27SO55B:U'6BINI91)2?KJHV#5,[JH
MZVEF39$S2%8F73%PJB@*RQS@FBF8P&W34H,87NY`F8Z<=('-5UX6]I?45K"Y
M@=Q-,</=&)AZVI#3IIB@HF!90E(SC%.2IWM?+S76G;.>&-6;K&12,N(&4$5N
M&KO)E29<QIHT57TKN<EW6W2]*/I;2/S;]4E-U_$)O)6GZ;N2O"/J5FYI4R[A
M9*1GF;)[(Q)'ZJIBB)6BY,S[=TNT&@2-K:!1,+^D;S9_JF>M^?2H_IJ?6#?1
ML[09-_#_`%'K?FX[-]9\%=0ZIVT_+NN;O`ZE^'W]W9A*5&=9H\FB;W<RLTN<
MM[0W1%CJG>=H])VE::FAC*=(;C04XSH&#/4DU++HF,B+UE<&J8YJS4`Y=])J
M<Y`[D1P)@;$5?.*.V:-&K!JV8LFZ+1FR;HM&C5NF5)!LV;IE10012(`$3212
M(!2E````#+#6=7&!"0[=@]`X$)K&D[3:VTR47<VB&CV+?0M::@[XWB@V,8T4
M;,X*#NQ7<C5\?31D5B%`ZT*B_P""H8H"0Y@S`1#$7-:\%KP"TZC:I[9#@YI(
M<-:=*4A"!ND*4A0Z"E*!0#W.@``,#6M8-E@`'-8HN<YQJXDGG7K$DDL"%3X*
M7$!7A)\4`$`4W"\0`-T@!\MX`'W<0ZN/;ZS9;UG+05\.E3ZQ^SL;1V.2MG@5
M3$U!?(J",8S4%,P\FW;.XZ4BI"/?-7B9%6KAH\:JMW"3E-0#$.BHDH(&`0$!
M#`A<_#V<NC'MN.=)J6M]1CLRU"43!7MI224B7?%AWT3!5<]84JH=0=TSYH#E
M`3-S9#D([WNX06F4U8"B\.<\BDORIM?95DR*E)IEN6N0#E`P%6;PRBR"I<^@
MZ2I`,4?<$,-4Q[XZ5"%['S$-":0=4\\'$Z\XU+-X<^9QX(-&-JZ$?);J?0"@
MK2)\Q_8``P@K)]X="+SPU0E@0@M*5_O@%T_Z+XO^S7:O`=*T?<K`O:^;6W%:
MU'I#U!,$Y%Y;J#;R]#+B5`5X6GZV:R[BI(YY)'()NK*SS=VFW3X@%*MU42E$
M1*(`%$)TA3J<F?FQ:>M>VGRVU`L*HB*4U(VUH"F:6N':.8=(1TV^<TO#-X9>
MK*.;+<).H:=EDXWK9@9"L9@"P)+@00#,5<C"TUU*;3`JUK+S,6IX/5^P-,\#
MMOYR>%X-1X?;W//M;N99>&][;Q_?9[>G`G4KGW>R?2SF7YCUW9.<D#R$S*Z?
M9IPH^D5@6?OWIJGB3KJ\54156<"B01.(;=T!SV806F;<'2NB]AK*E@0E@0M/
MW^JB;HJS-QZKIQR#.<@J5E)&,=&2!8$';=`3)*<(V0'W3>YCK3.+B#%>%<L,
M<XAP1XBQ:Z8?+)$^FULO:VH--=%S[*W!<.XCS#PC`\789,-O5^CCD;6FTUSJ
M$5U*&^G]>FK-R")6[:)J(ADN&B"%#'.JJ9,`WE!6:&.98Y0#NMGW1QYD8-WO
M>\7.&M@9=[ZPMHW9N!))&D[3"=H\MB]!\5[L&14)<Z5\]T<'5-;X`!751P%!
MR++/IPZP?T%0_P"@Y3_4QR+XKN\QZI9[/E\2_!^&S('UF[_NQ^-4'.N?5Z@@
MJJK1K1J0I1S<+4)(E32$>@QA4*4F0#^R.*I^]EWE(8G22X9'&P#>-PDH.<U%
M%;#W:,A)96L9B$CW$[HOL=3S66K9^E+5C?FZ^H&FJ'N%)QY(1S"U.[=Q;.FT
MX4YUF,,L\9**&`YE.Y5*!@SZ0QSWN\]XG-_,/.:X<)\:7B$85)=+T]\3+L("
M71PE[";2;#0\ZX9GCD9E?P-E5?.).%(93B3+Q=FMD?>#,`'S!CP+`-%G,I([
MT7RM3IWH=U<N]%:PUO:!CWK%A)U;43@&,#%+R2Y6S,TI(J`#:/;K+F`O$5,0
M@".T<>E"^!P";!I42FJ_GDZ/:(MC/0>EFX49JVU*UE"2<19JS=BFKZYLO457
MND3-6'A@*21D2Q$4R55!9<RIBJ'2(()E,(X%,1NK5U@6BO9_^5)<?1!1MR]2
M6IKA!JAU+&1?3T%QR.W-"T>L\&>;0DNN!!+VID99TJZ?`0X\'B`B;NR&*"3D
M>'6#0%(/SF?LJ-?O]6"Z/_(5L-1CWQTJ%'V/SU)]4']:M3_T_;7""G/O#H1<
M&&J4L"$%I2O]\`NG_1?%_P!FNU>`Z5H^Y1:>I;359W5O9NL+$WUI%C65OJS8
M*-'[!VFGUJ/=\)0C*;A79B'4C)N+45%1LX3R.F?[@B`BH!+34:5SMN8UR)M9
MO+&KASJ(TPS-:7-L?3$R,_3%S;;J2B5U+4-TEQ.T+745#)@^30C@'(THW*JP
M%+=%8Y5!,4$M3)&O%#I4E/*E]J'FDI.F;%<Q@47L:[.RA:=U)PS%8'S9RNJ@
MT:)72AD14%5J`9"I+-RG4$YCG<%*4`'`H/BUM1M_;BC.QGG&[64YYO\`L[VO
M[;>&8_LIV5\'^%NT?A_K'@OP'X,_*.M<7@\'N][=VX:ST-::US6K/SP<E;GV
M+0M<"M3MHJ;N.YI&:?N6ZK5@ZLI=&$4B(BMSH`"BIHN(+)#)%`H")NJ9!A+4
M?]2.S2NF#&R+&8CF$M&.4GL;*,VLA'O$#@=!VR>H$<M7*)PV'2704*8H^Z`X
M:RJ]P(2P(5J;J3\CAJ<6SQ,HB@[;B*2Y"F$,Q2<)=T`#E_FF#%<L,4\9AG:U
M\3A0@@$$<X-A4XY)(7B6)Q;(TU!!H1T$+T5HT)D!&S<@!T;J*9<O\&10RQ%M
MVN[-R-@Z&@?,I&>=UKGO)Z2O?`1^12_W9/O8EU47HM\`4>MD])WA*0H("&0H
MI"`]("F00_Q98##$10M;3H"?6RBT.=X2J/4&(+).09M0<(;_``5P02!9+B$%
M-3AJ`7?+OD'(<AVABK^3NG6MG$4?7,KLNV145%#0TJ*BP\RG_-7GJW0]8_JG
M4JW:-#0U%16AH;0L/N?;2A[RV\K.U5RJ=CJLH.OZ<E:5JNG99N1U'RT),LU6
M+YHX14`2B"B"PY#TE-D(;0QI5`-+1I7.]N7;2_WLS_,K@[IT?%2E>Z4+HOW+
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M)G,<A#D,9(P%5*4Q3&3,8I3@4X`(B0PD,`@`^X(#@5"\K(HN$E$'"22Z"Q#)
MJHK)E5253.&1DU$S@8AR&`<A`0$!#`A!?^T,\C6T+6TMQ]>VE:F6=OJMH9$]
M5WNMM`()-*3JVG3*'\.UK#195"IQE3-5E2*N$6J8%>B<ZA@W@'-*^*0UV2AQ
M?K*M07U17T(^VTMV5^D-X.ZYOGZUYG>R7:+S<=>_&>"NWG_$/?[V[^"RX>S!
MJ5NR.LVN9&S\]WDQ(\R6WD-=.RPPM/:JK5Q[Q"!6D3),(RZ%+G*556AZ@?`G
MNH/TE$BGC7BHY(*!PS&!(Y@P*B.38TZ%"?RNN>5=OEOOT=!_-'H*YM/4O;UP
MG3%&5]-T_++UA;9@T.FS9P%1LG90>5#1S9-(09N6X'402W?]D&PZ5-\8=Y3$
M8;9[7UHNOY!M*@M)J=LK6C%TW37,E%W!IHT@Q,=+BG:2D<I($>1S]N&8*HJD
M*=,P"`AAJDM<-(6MM4'-(T+Z2*'GZQNMJ)MH#V'CW3N/H:G:LA)^O*G=MTSF
M3BZ=IF.>KR,@[64+NB)2;B89F,(`&!`8XFE$R7E@WRKZX?+XOGKID8I6GJXU
M#W9OE>Z!A9(AGK2%I4]42#6W\:@1<3BX8M8!!/=VB40-LQUWFUQ+BG!V6V,\
M48,6#%;E<))8MINTW;:VHJTZ1S+G>7'#^'<3\?85PYB@<<-O=\CBDV3LNV7&
MAHX:#SJ\8\RN^R2`$<4?2,DIL$7!F,J@.0@&S<:B">WIQYL7/OTYN1PALV&8
M;._TNKF;^AEB^]+SW/,LGR[46(7^%GH[<1_2ZU7OUF%[_P";^C_WO/??QJ^.
MS-;U-AGU;QXUG^#G+;UKB'UH$OK,+W_S?T?^]Y[[^'\=F:WJ;#/JWCQH^#G+
M;UKB'UH%NG3!K0NY>J^M/T+4\=3\53DE%5.^<M8Z.6(X%6,BEGC0I';H!6*4
MBQ`SV]T&P<=I9"=Z+,C-+-RY<)8]!<[O@D]WO3W-CC(=6*$O91[_`"@`X6\N
MM==9T=W?@/+K+*]\38-+>I\7AGN[&NDD!;224,?5K;"2#9R*5S'H<OAM-1UH
MZ-K+:[+!UEI^O?`H2=.U.P6+$SB31HM4%$U`4N<;5=+.W22@Q\U%N"E.0Y<M
MX`W3;!P*37%IJ$##9VXFN/V9K5W*6[NW3]1W0T37-J3C/G\4VD5Z+K"(%1-%
M&N**>*@G&P%SHJ'1(#QD<2&6`G#5`2@7"M6BC96U\Y'4:?M4>FK6_95C<2RM
MQ*6N-;RNH-1H^:H/V(RL:$HR,D_IZJ8%18[R$FVA%C).6C@A5$U"F*(;,-9B
M"TT*!U7M]?SV;'F;REYD:#JJXFA>\3Q[3HU'3C)XYCI>W<W)'EV-.NW:12-&
M=P;8JN#\%!P8".]WBES34*.$M%1*VGG(TK3[S)]#FIZCX>LK1:E+53+:68$?
M*P,C6$'"5?!&,CQU&%2TQ(OT96#DVR>U5!<A3%#;T8:H+'`T(3*M>7.XTQ:=
M*4?T#I[JF,U3:K*R;JT[:ZSUEG:5>O$JNED3M85U6#FFU7B<#'-W:J:HIJF(
MNN0,DPVY@="DV,FTV!8?R*^7'=#1[;.[6H/5(5LOK`U@5@ZN1=HI>$=W2T>]
MDI"884J\40*5$'Z\K*NI-TF7/JZ[T4!R%(0`1(X.-&[H3.9'FXVNT*<[G798
MG5#-2-*V9NHCIZDJ'KU5!XO`T;5Z=D*`0DR3^8]79T_)(G()GA`W6ZJ9Q5'+
M+"4M@NC!&E$0TAK!TJ7`ITE6T3J,LM5%,J-B/"3L+<>E'T:+53/<7ZTC)F3!
M,V73GAJK9=R*`WG1\V>R%8V`K[0IHVE$-5NIS4C%JVN:4]9I,MP8VBFDVL+:
M1=S4C!"^CBSR`(@";`QA4`A^(<`*`9I6,8:[3K`%'S_\VESOJ=.P_":_3A\X
MGTD.R_6T>JY=E^R_F7Z_P\NM]F_RW//>\,?@,]W9@U*?6C;^BCAL-9T/-S\_
M1/3?V97><CZ]_EATF]$/YT_TL\"MCTZ_D7-GNAY=2_D5[UOZ&_(;WAO%OSOR
MOQL):1H6U-*WI4B_5T_'MO6U]&O?"7?_`,S\I\3>P(*ZO^F?U#K1^JQZ&X;T
M(^J9WE_$#_QS\A\3/'%N-_=._P#]/[,_MW8]'_(_=>ES+];A+WFN?;NT-['V
MK3]S^\]'G6=T+XK4]7CWS;R5[Q[W#W_W?@?$QU5PG_3S[EZ6]D^SW=?^7F79
M'$W;6^]FAW:=_>U?/SK-?U/XY1_;:XY[?2_4_@_MM'M]8-1OI7B_5Y[UG_)7
MTA][J>+_`)C]N?-YXXIPS_Z)=O<O[.\=D_J6Z?L_H_MOHU7)>(?<:;WKWX.T
M]@WAO_2_9<]$Z?'T$ND4L"%'/S5O4HNOZH_>B'KM>@?H6\=?G?\`:7SN$5)F
M\-/R:4`YI<]8(?1EXI:_9O\`CWQB[[Z^-\EAC2M)T>-'P2/V><3Y!>C!CZ]G
MDOWE_P!V?C?*_$SPM2S>=XESRM4OI3=?9!>5SGU7/(#WY.^/Y/\`^7`5I&CS
MM")\]GO\J9S[)OQ1(>J]ZT/OTO*G^3/P/N8:JDT:_F1:F!4H6[GY]_L/LB/$
MK?UU/3_WO_$?]R_`^;RP>!71_P"+Y$&W'^DY;[./Q6IT>BG\0V_$?G'X/SF_
IA*_5K1K'(5\5R_V2WBA;U&O3-[]EZ4?W5\/YK@X%1)\ORHEW#5*__]D_
`
end
</TEXT>
</DOCUMENT>
</SUBMISSION>
